Image

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

Recruiting
18 years and older
All
Phase 2
  • Technical (Original)
  • Simplified (AI rewritten)

Powered by AI

Overview

This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.

Eligibility

Inclusion Criteria:

  • Mean eGFR
  • Clinical evidence of active kidney disease
  • Been on supportive care
  • vaccine requirements
  • Females must not be pregnant or breastfeeding
  • Men must agree to use acceptable contraception and not donate sperm
  • IgAN: confirmed disease by kidney biopsy performed within 60 months prior to screening
  • C3G/IC-MPGN: confirmed disease by kidney biopsy performed within 18 months prior to screening

Exclusion Criteria:

  • Hereditary or acquired complement deficiency
  • Kidney transplant or renal replacement therapy
  • History of solid organ transplant
  • Other kidney disease
  • History of recurrent invasive infections
  • Received complement inhibitor treatments
  • Active systemic viral, bacterial, or fungal infection
  • Liver dysfunction
  • No donating blood

Study details
    IgAN
    C3G
    Complement-mediated Kidney Disease
    IgA Nephropathy (IgAN)
    IC-MPGN

NCT06989359

ADARx Pharmaceuticals, Inc.

1 February 2026

Contact a study center
Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.